| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 3-dioxygenase; IDO 1; IDO; IDO1; INDO; indolamine 2,3 dioxygenase; Indole 2 3 dioxygenase;;IDO 1 |
| WB Predicted band size | 45 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IDO 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于INDO(吲哚胺2.3-双加氧酶)抗体的3篇示例参考文献(注：部分内容为示例性概括，具体文献需通过学术数据库进一步验证)：
---
1. **文献名称**：*Targeting Indoleamine 2.3-Dioxygenase (IDO) in Cancer: Antibody-Based Therapeutic Strategies*
**作者**：Soliman, H.H. et al.
**摘要**：本研究开发了一种靶向IDO的单克隆抗体，通过体外和动物模型验证其抑制IDO酶活性的能力，证明其可逆转肿瘤微环境中的免疫抑制状态，增强T细胞对肿瘤的杀伤作用。
2. **文献名称**：*Anti-IDO Antibodies Enhance Anti-Tumor Immunity by Blocking Tryptophan Catabolism in Murine Models*
**作者**：Muller, A.J. et al.
**摘要**：通过构建抗IDO抗体，研究团队在小鼠模型中证明该抗体能够有效阻断色氨酸代谢通路，减少调节性T细胞(Tregs)的浸润，并显著增强化疗药物和免疫检查点抑制剂的协同抗肿瘤效果。
3. **文献名称**：*IDO-Specific Antibodies in Breast Cancer: Impact on Tumor Microenvironment and Chemotherapy Response*
**作者**：Hou, D.Y. et al.
**摘要**：该研究利用抗IDO抗体处理乳腺癌模型，发现其可通过抑制IDO介导的色氨酸耗竭，减少肿瘤相关巨噬细胞(TAMs)的免疫抑制表型，从而增强化疗的疗效并延长生存期。
---
**备注**：上述文献为示例，实际研究中建议通过PubMed、Web of Science或Google Scholar以关键词“IDO antibody”或“Indoleamine 2.3-dioxygenase monoclonal antibody”检索最新及高引用的论文。
**Background of INDO Antibody**
The INDO antibody targets indoleamine 2.3-dioxygenase (IDO), a heme-containing enzyme that catalyzes the rate-limiting step in tryptophan metabolism via the kynurenine pathway. IDO is widely recognized for its immunosuppressive role, particularly in the tumor microenvironment and inflammatory conditions. By degrading tryptophan and producing kynurenine metabolites, IDO suppresses T-cell activation and promotes regulatory T-cell differentiation, enabling immune tolerance. This mechanism is exploited by cancers and pathogens to evade host immune responses.
INDO antibodies are essential tools in studying IDO expression and function, aiding in diagnostics and research on diseases like cancer, autoimmune disorders, and chronic infections. In cancer research, IDO overexpression correlates with poor prognosis, making it a therapeutic target. Antibodies against IDO are used in immunohistochemistry, flow cytometry, and Western blotting to assess its expression in tissues or cells. Additionally, therapeutic strategies using IDO inhibitors or blocking antibodies aim to counteract immunosuppression, often in combination with checkpoint inhibitors (e.g., anti-PD-1/PD-L1).
Despite promising preclinical results, clinical trials targeting IDO have shown mixed outcomes, highlighting the complexity of its role in immune regulation. Nonetheless, INDO antibodies remain crucial for unraveling IDO's biological impact and advancing immunotherapeutic approaches.
×
